Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: J Med Chem. 2019 Jun 25;62(13):6175–6189. doi: 10.1021/acs.jmedchem.9b00428

Figure 3. Effects of ezetimibe and pranlukast on enzyme activity and thermal stability of hrGALNS.

Figure 3.

A) Recombinant GALNS was incubated with the fluorogenic substrate 4-methylumbelliferyl-β-D-galactopyranoside-6-sulfate with or without ezetimibe or pranlukast. GALNS activity was measured after an 18 h incubation as described in the Materials and Methods section. The results are reported as percentage of activity relative to the results observed without ezetimibe or pranlukast. B) Thermal stability was carried out by thermal shift assay. The hrGALNS was incubated with or without ezetimibe or pranlukast. The Tm was calculated by plotting the first derivative of the fluorescence emission as a function of temperature (−dF/dT). All assays were performed in triplicate.